Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists-Reference-Cited by-同舟云学术

Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists

Published:2024-07-10 Issue:30 Volume:45 Page:2748-2751
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Ostrominski John W¹²^ORCID,Solomon Scott D¹^ORCID,Vaduganathan Muthiah¹^ORCID

Affiliation:

1. Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School , 75 Francis St, Boston, MA 02115 , USA

2. Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Harvard Medical School , Boston, MA , USA

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurheartj/article-pdf/45/30/2748/58789527/ehae414.pdf

Reference24 articles.

1. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials;Butler;Lancet,2024

2. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors;Cherney;Med,2021

3. Mechanisms and benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction;Pandey;Eur Heart J,2023

4. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets;Borlaug;Cardiovasc Res,2023

5. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial;Borlaug;Nat Med,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heart failure and ischaemic heart disease: new challenges and opportunities;European Heart Journal;2024-08-07